174 related articles for article (PubMed ID: 30905435)
1. Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.
DiSilvestro PA
Gynecol Oncol; 2019 Jun; 153(3):479-486. PubMed ID: 30905435
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
3. Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer.
Ozols RF
Cancer Invest; 2004; 22 Suppl 2():11-20. PubMed ID: 15573741
[TBL] [Abstract][Full Text] [Related]
4. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Eskander RN; Kauderer J; Tewari KS; Mannel RS; Bristow RE; O'Malley DM; Rubin SC; Glaser GE; Hamilton CA; Fujiwara K; Huh WK; Ueland F; Stephan JM; Burger RA
Gynecol Oncol; 2018 Jun; 149(3):525-530. PubMed ID: 29550184
[TBL] [Abstract][Full Text] [Related]
5. Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
Monk BJ; Chan JK
Ann Oncol; 2017 Nov; 28(suppl_8):viii40-viii45. PubMed ID: 29232474
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
7. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
9. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
10. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Garcia-Soto AE; Java JJ; Nieves Neira W; Pearson JM; Cohn DE; Lele SB; Tewari KS; Walker JL; Alvarez Secord A; Armstrong DK; Copeland LJ
Gynecol Oncol; 2016 Dec; 143(3):484-489. PubMed ID: 27726923
[TBL] [Abstract][Full Text] [Related]
11. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.
Tewari KS; Java JJ; Eskander RN; Monk BJ; Burger RA
Ann Oncol; 2016 Jan; 27(1):114-21. PubMed ID: 26487588
[TBL] [Abstract][Full Text] [Related]
12. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
Darcy KM; Brady WE; McBroom JW; Bell JG; Young RC; McGuire WP; Linnoila RI; Hendricks D; Bonome T; Farley JH;
Gynecol Oncol; 2008 Dec; 111(3):487-95. PubMed ID: 18834621
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy for ovarian cancer: current status and new treatments.
Ozols RF
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
[TBL] [Abstract][Full Text] [Related]
14. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
15. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
Cohn DE; Barnett JC; Wenzel L; Monk BJ; Burger RA; Straughn JM; Myers ER; Havrilesky LJ
Gynecol Oncol; 2015 Feb; 136(2):293-9. PubMed ID: 25449568
[TBL] [Abstract][Full Text] [Related]
16. Gynecologic oncology group trials in ovarian carcinoma.
Ozols RF
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-10-S2-12. PubMed ID: 9045325
[TBL] [Abstract][Full Text] [Related]
17. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
[TBL] [Abstract][Full Text] [Related]
18. Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.
Seamon LG; Richardson DL; Copeland LJ
Clin Obstet Gynecol; 2012 Mar; 55(1):131-55. PubMed ID: 22343234
[TBL] [Abstract][Full Text] [Related]
19. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
20. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Grabosch S; Tseng G; Edwards RP; Lankes HA; Moore K; Odunsi K; Vlad A; Ma T; Strange M; Brozick J; Lugade A; Omilian A; Bshara W; Stuckey AR; Walker JL; Birrer M
Gynecol Oncol; 2017 Jul; 146(1):137-145. PubMed ID: 28483269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]